ABSTRACT -The effects of mirabegron on plasma gonadotropic and steroidal hormone levels in rats ----tary gland, adrenal glands, liver, testes, epididymides, prostate, seminal vesicle, ovaries, uterus, or vagina at any dose. In males, no treatment-related changes in levels of luteinizing hormone (LH), follicle stimu--observed at any dose in any stage of the estrous cycle. Taken together, these results suggest that mirabeday or greater.
INTRODUCTION
Mirabegron is a selective and potent human 3 -adrenoceptor agonist (Takasu et al., 2007) that has been approved for the treatment of overactive bladder (OAB) in Japan, the United States, Europe, Canada and Australcurrent standard of care (Athanasopoulos and Giannitsas, 2011) . OAB treatment studies found that oral administration of mirabegron at a maximum recommended human -icantly reduced the change from baseline for both the mean number of incontinence episodes per 24 hr and the mean number of micturitions per 24 hr compared to a placebo (Khullar et al., 2013) .
-(seminal vesicle, prostate, and uterus), and in females, prolonged diestrus and decreased numbers of corpora and live fetuses. These findings resulted in the inclu--ing that patients of reproductive age should refrain from using mirabegron (Astellas Pharma Inc., 2013).
The current study evaluated the potential mechanism for these findings by determining if mirabegron alters plasma gonadotropic and steroidal hormone levels in rats. 
Effect of mirabegron on

MATERIALS AND METHODS
Animals
Charles River Laboratories Japan, Inc. (Shiga, Japan).
and humidity (43 to 65%) controlled rooms under a 12-hr light-dark cycle (light period from 07:00 to 19:00). All
Institutional Animal Care and Use Committee of Shin -al.
Test substance and administration
Mirabegron (Astellas Pharma Inc., Tokyo, Japan), suspended in a 0.5% methylcellulose (Shin-Etsu Chemical Since several male and female rats died at a dose of 
Statistical analysis heterogeneous, a Dunnett's multiple comparison test (sig-
RESULTS
Mortality and clinical signs -tested. (Table 4) .
Body weight and food consumption
Hormone Assay
In male rats, mirabegron administration at doses up to estrous cycle-related changes in gonadotropic and sex steroid hormone levels (Figs. 4 and 5) . During proestrus, peak prolactin levels occurred by 15:00, peak LH lev---strus, progesterone levels increased slightly in a biphasic -LH, FSH, prolactin, estradiol, progesterone, or corticosterone levels at any stage of the estrous cycle. Statistically significant changes in plasma DHT levels in males and plasma FSH, progesterone, prolactin and -centration relationship.
DISCUSSION
Administration of mirabegron to rats, at doses up on either gonadotropic or sex steroid hormone levels in of the accessory reproductive organs in either sex at up to 24 79 and 36 times higher than those reported for humans 24 : 341 ng· female AUC 24 : 512 ng· --tion during the early phase of treatment (Cooper et al., 1970) . Increased food consumption during the late phase of treatment suggests increased lipolysis and thermogen- et al., 2009 ). compared to the control. As isoproterenol (a nonselective -terone level (Daniels et al., 1993) , the changes in corticosterone levels observed in males might have occurred 3 -adrenoceptors might induce changes in corticosterone levels occurred in females and high corticosterone levels in males remains unclear.
In conclusion, no treatment-related effects of mirabe--suggesting that mirabegron is unlikely to disrupt gonadotropic or steroidal sex hormone levels directly. The increase in adrenocortical hormone levels noted in males 
